Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Trial Profile

NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brachyury peptide vaccine (Primary) ; CST 101 (Primary) ; ETBX 021 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; GI 4000 (Primary) ; Inbakicept (Primary) ; Avelumab; Bevacizumab; Capecitabine; Cyclophosphamide; Fluorouracil; Folinic acid; Fulvestrant; Omega-3-acid ethyl esters; Oxaliplatin; Paclitaxel
  • Indications Carcinoma; Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ImmunityBio
  • Most Recent Events

    • 23 Aug 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 26 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Dec 2017.
    • 27 Jun 2017 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top